Inventor · disambiguated record
Huynh-Hoa Bui
Also filed as: BUI HUYNH-HOA
25 granted patents·41 pending applications·49 citations·filing 2014–2025
94Inventor score
Top patents by PatentIndex Score
66 records- 0193US9994855B2Compositions and methods for modulating growth hormone receptor expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Jun 12, 2018·9 cites·43 claims
- 0293US9670492B2Modulation of prekallikrein (PKK) expressionIONIS PHARMACEUTICALS INC·Filed 2014·Granted Jun 6, 2017·15 cites·29 claims
- 0392US10793856B2Compositions for modulating Tau expressionBIOGEN MA INC·Filed 2017·Granted Oct 6, 2020·9 cites·58 claims
- 0491US11840686B2Modulation of prekallikrein (PKK) expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Dec 12, 2023·1 cites·21 claims
- 0591US11591595B2Compositions for modulating Tau expressionBIOGEN MA INC·Filed 2020·Granted Feb 28, 2023·2 cites·34 claims
- 0689US10774333B2Modulators of PNPLA3 expressionIONIS PHARMACEUTICALS INC·Filed 2019·Granted Sep 15, 2020·2 cites·9 claims
- 0789US10100310B2Modulation of prekallikrein (PKK) expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Oct 16, 2018·5 cites·19 claims
- 0888US11633483B2Modulators of PCSK9 expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Apr 25, 2023·1 cites·15 claims
- 0987US10793862B2Compositions and methods for modulating growth hormone receptor expressionIONIS PHARMACEUTICALS INC·Filed 2019·Granted Oct 6, 2020·1 cites·56 claims
- 1087US2024401054A1Compositions and methods for modulating pkk expressionIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1186US11021710B2Compounds and methods for reducing FXI expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Jun 1, 2021·1 cites·18 claims
- 1286US11000595B2Modulators of PCSK9 expressionIONIS PHARMACEUTICALS INC·Filed 2019·Granted May 11, 2021·1 cites·7 claims
- 1385US12091662B2Compositions for modulating tau expressionBIOGEN MA INC·Filed 2023·Granted Sep 17, 2024·0 cites·15 claims
- 1484US11053500B2Modulation of prekallikrein (PKK) expressionIONIS PHARMACEUTICALS INC·Filed 2018·Granted Jul 6, 2021·1 cites·20 claims
- 1584US2024076675A1Modulators of pnpla3 expressionIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1684US2024076676A1Modulators of pnpla3 expressionIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1783US2025283081A1Compounds and Methods for Modulating UBE3A-ATSIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1882US11241451B2Modulators of IRF4 expressionIONIS PHARMACEUTICALS INC·Filed 2019·Granted Feb 8, 2022·1 cites·22 claims
- 1980US2023118177A1Compositions and methods for modulating growth hormone receptor expressionIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2080US2023321255A1Modulators of PCSK9 ExpressionIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2178US2023147811A1Modulators of growth hormone receptorIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2277US2024327838A1MODULATORS OF ENaC EXPRESSIONIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2375US11781143B2Modulators of PNPLA3 expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Oct 10, 2023·0 cites·14 claims
- 2475US2025320505A1Compounds and Methods for Reducing KCNT1 ExpressionIONIS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2574US11312964B2Compositions and methods for modulating growth hormone receptor expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Apr 26, 2022·0 cites·20 claims
- 2673US12042510B2Modulators of IRF4 expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Jul 23, 2024·0 cites·17 claims
- 2771US2024316092A1Compounds and methods for increasing stmn2 expressionIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2870US12281305B2Compounds and methods for reducing prion expressionIONIS PHARMACEUTICALS INC·Filed 2019·Granted Apr 22, 2025·0 cites·29 claims
- 2970US2024026353A1Compounds and methods for modulating scn2aIONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3070US2021108211A1Modulators of growth hormone receptorLONIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3168US2024158791A1Method of treating fatty liver diseaseASTRAZENECA AB·Filed 2023·Application pending·0 cites
- 3268US2025270556A1Compounds and methods for modulating scn2aIONIS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3367US12384814B2Compounds and methods for reducing app expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Aug 12, 2025·0 cites·32 claims
- 3467US2022290137A1Compounds and methods for reducing spdef expressionIONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3566US10526604B2Modulation of nuclear-retained RNAIONIS PHARMACEUTICALS INC·Filed 2017·Granted Jan 7, 2020·0 cites·20 claims
- 3666US2023167446A1Compounds and methods for reducing psd3 expressionIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3765US11214803B2Modulators of YAP1 expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·0 cites·23 claims
- 3865US2025051781A1Compounds and methods for modulating glycogen synthase 1IONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3965US2025177433A1Compounds and methods for reducing dmpk expressionIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4064US12018261B2Compounds and methods for modulating factor XIIIONIS PHARMACEUTICALS INC·Filed 2021·Granted Jun 25, 2024·0 cites·58 claims
- 4164US11833168B2Compounds and methods for increasing STMN2 expressionIONIS PHARMACEUTICALS INC·Filed 2019·Granted Dec 5, 2023·0 cites·36 claims
- 4264US2025109396A1Compounds and methods for modulating progranulin expressionIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4363US11840689B2Method of treating fatty liver diseaseASTRAZENECA AB·Filed 2021·Granted Dec 12, 2023·0 cites·7 claims
- 4463US2020056185A1Compositions and methods for modulating pkk expressionIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4563US2022315927A1Modulators of yap1 expressionIONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4663US2018320188A1Compositions and methods for modulating growth hormone receptor expressionIONIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4762US2025346907A1Compounds and methods for reducing glycogen synthase 1IONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4862US2024191233A1Compounds and methods for reducing nlrp3 expressionIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4962US2021139906A1Compounds and methods for reducing spdef expressionIONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 5062US2022177893A1Compounds and methods for reducing kcnt1 expressionIONIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 66 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Huynh-Hoa Bui files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →